Author(s)

Katia Margiotti^1*, Marco Fabiani¹, Francesca Giorlandino², Marina Cupellaro², Sabrina Emili², Alvaro Mesoraca¹, Claudio Giorlandino^1,2,3

¹ALTAMEDICA, Human Genetics Lab, Rome, Italy.
²ALTAMEDICA, Department of Biochemistry, Rome, Italy.
³ALTAMEDICA, Department of Prenatal Diagnosis, Fetal-Maternal Medical Centre, Rome, Italy.

In the present study, we analysed the results from the use of serological tests for the evaluation of the antibody response to SARS-CoV-2 virus, with the aim of verifying the seroprevalence for SARS-CoV-2 virus infection in Rome. Evaluations related to the seroprevalence are important for defining the epidemiological parameters of this disease. We therefore analysed the data deriving from 1586 subjects, residing in the geographical area of Rome, subjected to a rapid test, capable of detecting the presence of specific IgM and IgG class antibodies directed against the SARS-CoV-2 virus. Among the 1586 cases, 83 had positive conversion of IgM antibody and/or IgG antibody and 1503 tested negative. Out of 83 positive cases, 48% (40/83) samples resulted positively for both IgM and IgG, while 45% (37/83) were positive for IgG only, and 7% (6/83) for IgM only. The prevalence of anti-SARS-CoV-2 antibodies in the considered geographical area was 5% (83/1586), and 54% (45/83) of our population was an asymptomatic carrier. The study was performed to better evaluate the population prevalence in the studied geographic area. To our knowledge, this is the first study carried out in the Lazio region reporting data related to the asymptomatic carriers.

COVID-19, SARS-CoV-2 Virus, Antibodies IgM, IgG

Margiotti, K. , Fabiani, M. , Giorlandino, F. , Cupellaro, M. , Emili, S. , Mesoraca, A. and Giorlandino, C. (2021) Local Transmission of SARS-CoV-2 Virus in Rome, Italy: A Single Center Experience. Advances in Infectious Diseases, 11, 42-48. doi: 10.4236/aid.2021.111006.